Status:
UNKNOWN
Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
Covid19
COVID-19 Prevention
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
COVID-19 affected more than 9 million of people with more than 130 thousand death in India. If adequate preventive and therapeutic measures are not taken, India has very high risk of affecting million...
Eligibility Criteria
Inclusion
- Gender: Male/Female
- Age of ≥18 years
- Asymptomatic individual with direct contact with laboratory confirmed COVID-19 cases
Exclusion
- 1\. Symptomatic individual 2. Health care worker 3. Individual who will not give consent for HCQ prophylaxis 4. Contraindication for HCQ therapy 5. Pregnancy 6. Individual who received COVID-19 vaccine
- \-
Key Trial Info
Start Date :
March 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2021
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04858633
Start Date
March 22 2021
End Date
June 30 2021
Last Update
June 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Post Graduate Institute of Medical Education and Research
Chandigarh, India, 160012